| Literature DB >> 32316144 |
Inês Francisco1, Maria Helena Fernandes2,3, Francisco Vale1.
Abstract
Preservation of the alveolar bone is a determinant in the outcome of orthodontic treatment. Alveolar bone defects or a decrease of their height and width may occur due to common reasons such as inflammation, tooth extraction, or cleft lip and palate. The aim of this systematic review was to investigate and appraise the quality of the most up to date available evidence regarding the applications and effects of platelet-rich fibrin (PRF) in orthodontics. This study was carried out according to preferred reporting items for systematic reviews and meta-analyses guidelines using the following databases: Medline via PubMed, Cochrane Library, Web of Science Core Collection and EMBASE. The qualitative assessment of the included studies was performed using Cochrane Risk of Bias tool and ROBINS-I guidelines.Entities:
Keywords: bone regeneration; orthodontics; platelet concentrate; platelet rich fibrin
Year: 2020 PMID: 32316144 PMCID: PMC7216087 DOI: 10.3390/ma13081866
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Research question according to the PICO format.
| Parameter | Assessment |
|---|---|
| Population (P) | Orthodontic Patients of any gender or age |
| Intervention (I) | Participants who underwent treatments approaches with the use of PRF with/without a combined biomaterial. |
| Comparison (C) | The control group consisted of participants that underwent treatments approaches without PRF. |
| Outcome (O) | Outcome were: hard tissue reconstruction of alveolar bone—assessed by volume of the newly formed bone (measured in cubic centimeter or percentage of newly formed bone); rate of tooth movement—assessed by the change in horizontal linear distance between the mid-marginal ridges of the adjacent teeth (measures in millimeters). |
Search Strategy for each of the databases
| Database | Search Equation |
|---|---|
| Medline (via PubMed) | (“Orthodontics”[Mesh] OR “Tooth Movement Techniques”[Mesh] OR “Orthodontic Brackets”[Mesh] OR “ Tooth Movement” OR “Accelerating Orthodontic” OR “Surgery, Oral”[Mesh] OR “Alveolar Bone Grafting”[Mesh] OR “Post extraction Socket” OR “Socket Preservation” OR “Guided Tissue Regeneration”[Mesh] OR “Bone Regeneration”[Mesh] OR “Tissue Scaffolds”[Mesh] OR “Bone Transplantation”[Mesh] OR “Bone Remodeling”[Mesh] OR “Bone Substitutes”[Mesh]) AND (“Platelet-Rich Fibrin”[Mesh] OR “Platelet Rich Fibrin” OR “Fibrin rich in growth factors” OR “Platelet concentrate” OR “PRF” OR “Second generation platelet rich fibrina” OR “osteoinductive biomaterials”) |
| Cochrane Library | (Mesh descriptor: [Orthodontics] OR Mesh descriptor: [Alveolar Bone Grafting] OR Mesh descriptor: [Bone Regeneration] OR tooth movement OR alveolar bone grafting) AND (Mesh descriptor: [Platelet-Rich Fibrin] OR PRF OR Platelet rich fibrin) |
| Web of Science Core Collection | TS = (platelet rich fibrin* OR platelet-rich fibrin * OR PRF* OR second generation platelet concentrate* OR platelet concentrate*) AND TS = (orthodontics* OR tooth movement* OR alveolar bone grafting* OR orthodontic brackets*) |
| EMBASE | (“Orthodontics” OR “Orthodontic tooth movement” OR “Orthodontic device” OR “Alveolar Bone Grafting”) AND (“Tissue regeneration” OR “bone regeneration”) AND (“Platelet-rich fibrin” OR “platelet AND concentrate”) |
Version 2 of the Cochrane tool for assessing risk of bias (RoB 2) [14].
| Bias Domain and Signalling Question * | Response Options | ||
|---|---|---|---|
| Lower Risk of Bias | Higher Risk of Bias | Other | |
|
| |||
| 1.1 Was the allocation sequence random? | Y/PY | N/PN | NI |
| 1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? | Y/PY | N/PN | NI |
| 1.3 Did baseline differences between intervention groups suggest a problem with the randomisation process? | N/PN | Y/PY | NI |
| Risk-of-bias judgment (low/high/some concerns) | |||
| Optional: What is the predicted direction of bias arising from the randomisation process? | |||
|
| |||
| 2.1 Were participants aware of their assigned intervention during the trial? | N/PN | Y/PY | NI |
| 2.2 Were carers and people delivering the interventions aware of participants’ assigned intervention during the trial? | N/PN | Y/PY | NI |
| 2.3 If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the trial context? | N/PN | Y/PY | NA/NI |
| 2.4 If Y/PY/NI to 2.3: Were these deviations likely to have affected the outcome? | N/PN | Y/PY | NA/NI |
| 2.5 If Y/PY to 2.4: Were these deviations from intended intervention balanced between groups? | Y/PY | N/PN | NA/NI |
| 2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention? | Y/PY | N/PN | NI |
| 2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomised? | N/PN | Y/PY | NA/NI |
| Risk-of-bias judgment (low/high/some concerns) | |||
| Optional: What is the predicted direction of bias due to deviations from intended interventions? | |||
|
| |||
| 3.1 Were data for this outcome available for all, or nearly all, participants randomised? | Y/PY | N/PN | NI |
| 3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data? | Y/PY | N/PN | NA |
| 3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? | N/PN | Y/PY | NA/NI |
| 3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? | N/PN | Y/PY | NA/NI |
| Risk-of-bias judgment (low/high/some concerns) | |||
| Optional: What is the predicted direction of bias due to missing outcome data? | |||
|
| |||
| 4.1 Was the method of measuring the outcome inappropriate? | N/PN | Y/PY | NI |
| 4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? | N/PN | Y/PY | NI |
| 4.3 If N/PN/NI to 4.1 and 4.2: Were outcome assessors aware of the intervention received by study participants? | N/PN | Y/PY | NI |
| 4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? | N/PN | Y/PY | NA/NI |
| 4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? | N/PN | Y/PY | NA/NI |
| Risk-of-bias judgment (low/high/some concerns) | |||
| Optional: What is the predicted direction of bias in measurement of the outcome? | |||
|
| |||
| 5.1 Were the data that produced this result analysed in accordance with a prespecified analysis plan that was finalised before unblinded outcome data were available for analysis? | Y/PY | N/PN | NI |
| Is the numerical result being assessed likely to have been selected, on the basis of the results, from: | |||
| 5.2 ... multiple eligible outcome measurements (e.g., scales, definitions, time points) within the outcome domain? | N/PN | Y/PY | NI |
| 5.3 ... multiple eligible analyses of the data? | N/PN | Y/PY | NI |
| Risk-of-bias judgment (low/high/some concerns) | |||
| Optional: What is the predicted direction bias due to selection of the reported results? | |||
|
| |||
| Risk-of-bias judgment (low/high/some concerns) | |||
| Optional: What is the overall predicted direction of bias for this outcome? | |||
| Y = yes; PY = probably yes; PN = probably no; N = no; NA = not applicable; NI = no information | |||
Robins-I tool for assessing risk of bias for non-randomised studies [15].
| Domain | Explanation |
|---|---|
| Pre-intervention | Risk of bias assessment is mainly distinct from assessments of randomised trials |
| Bias due to confounding | Baseline confounding occurs when one or more prognostic variables (factors that predict the outcome of interest) also predicts the intervention received at baseline. |
| Bias in selection of participants into the study | When exclusion of some eligible participants, or the initial follow-up time of some participants, or some outcome events is related to both intervention and outcome, there will be an association between interventions and outcome even if the effects of the interventions are identical. |
| At intervention | Risk of bias assessment is mainly distinct from assessments of randomised trials |
| Bias in classification of interventions | Bias introduced by either differential or non-differential misclassification of intervention status. |
| Post-intervention | Risk of bias assessment has substantial overlap with assessments of randomised trials |
| Bias due to deviations from intended interventions | Bias that arises when there are systematic differences between experimental intervention and comparator groups in the care provided, which represent a deviation from the intended intervention(s). |
| Bias due to missing data | Bias that arises when later follow-up is missing for individuals initially included and followed (such as differential loss to follow-up that is affected by prognostic factors); bias due to exclusion of individuals with missing information about intervention status or other variables such as confounders. |
| Bias in measurement of outcomes | Bias introduced by either differential or non-differential errors in measurement of outcome data. Such bias can arise when outcome assessors are aware of intervention status, if different methods are used to assess outcomes in different intervention groups, or if measurement errors are related to intervention status or effects. |
| Bias in selection of the reported result | Selective reporting of results in a way that depends on the findings and prevents the estimate from being included in a meta-analysis (or other synthesis). |
Figure 1PRISMA flow chart.
List of excluded studies.
| Study | Reason for Exclusion |
|---|---|
| Alhasyimi et al. [ | Animal study |
| Che et al. [ | Review article |
| Dukka et al. [ | Case Report |
| Janssen et al. [ | Evaluates PRP and not PRF |
| Stasiak et al. [ | Systematic review |
| Shetty et al. [ | Trial registration |
| Subbalekha et al. [ | Trial registration |
| Avinash et al. [ | Trial registration |
| Tehranchi et al. [ | Trial registration |
| Mazzone et al. [ | Not orthodontic field |
| Shah et al. [ | Technical note |
| Iskenderoglu et al. [ | Case Report |
| Dimofte et al. [ | Review article |
| Nadon et al. [ | Evaluate a derivate of PRF |
| Aras et al. [ | Case Report |
| Findik et al. [ | Case Report |
Characteristics of included studies on alveolar cleft reconstruction.
| Alveolar Cleft Reconstruction | ||||||
|---|---|---|---|---|---|---|
|
| Omidkhoda et al. [ | Movahedian Attar et al. [ | El-Ahmady et al. [ | Saruhan et al. [ | Shawky et al. [ | Desai et al. [ |
|
| 2018 | 2017 | 2018 | 2018 | 2016 | 2019 |
|
| Parallel-group RCT | Parallel-group RCT | Parallel-group RCT | Parallel-group RCT | Parallel-group RCT | Parallel-group RCT |
|
| Efficacy of PRF in the quality and quantity of maxillary alveolar cleft repair. | Efficacy of (i) combination of symphysis bone, allograft and PRF, and (ii) iliac bone graft, in the regeneration of cleft defects. | Use of autologous BMMNCs combined with PRF and nanohydroxyapatite as an effective technique for alveolar cleft repair. | Effect of PRF in alveolar bone grafting using volumetric analysis. | Effect of PRF in the quality and quantity of unilateral maxillary alveolar cleft repair. | Efficacy of PRF for secondary alveolar bone grafting. |
|
| Autogenous anterior iliac graft with PRF (n = 5) | Bone graft from allogenic bone material, chin symphysis bone and L-PRF (n = 10) | Autologous BMMNCs combined with nanohydroxyapatite and autologous PRF (n = 10) | Autogenous bone graft from anterior iliac crest with PRF (n = 17 alveolar cleft segment) | Autogenous bone graft from anterior iliac crest with PRF (n = 12) | Autogenous bone graft from anterior iliac crest with PRF (n = 20) |
|
| Autogenous anterior iliac graft (n = 5) | Autogenous bone graft from anterior iliac crest (n = 10) | Autogenous bone graft from anterior iliac crest (n = 10) | Autogenous bone graft from anterior iliac crest (n = 14 alveolar cleft segment) | Autogenous bone graft from anterior iliac crest (n = 12) | Autogenous bone graft from anterior iliac crest (n = 20) |
|
| 10 (4/6) | 20 (9/11) | 20 (12/8) | 31 alveolar cleft segments in 22 patients (13/9) | 24 (8/16) | 40 (19/21) |
|
| 9–12 | 8–14 | 8–15 | 6–28 | 9–14 | 9–18 |
|
| 3000 rpm, 10 min | 3000 rpm, 10 min | 3000 rpm, 20 min | 3000 rpm, 10 min | 3000 rpm, 10 min | 2900 rpm, 10 min |
|
| CBCT images (Planmeca, Finland, 2009). Exposure parameters: field of view of 90 × 100 mm, voxel size of 200 µm, X-ray tube kilovoltage of 88 kVp, and 8 mA. | CBCT Images (Cranex 3D, Sordex, Helsinki, Finland). Exposure parameters: 0.5 mm scan thickness for axial cuts. | Panoramic radiographs and CBCT images. Pain was measured with a numerical scale score reporting pain intensity. | CBCT Images (NewTom FP, Quantitative Radiology, Verona, Italy). Exposure parameters: 0.5 mm scan thickness for axial cuts. | CT scan (Philips Brilliance 32 Slice.Cardiac MDCT, Philips Healthcare, city, Netherlands) of upper jaw. The axial cuts were 0.625 mm thick. | Orthopantomogram, upper occlusal view, and CT scan (KODAK 9000C and KODAK 9000C 3D extra oral Imaging System, 2016; Carestream Inc., New York, USA). |
|
| 3 months. CBCT images: immediate postoperative and 3 months after surgery. | 12 months. CBCT images: before surgery and 12 months after. Clinical controls: 1week, 1, 3, 6 and 12 months. | 12 months. CBCT images: 6 and 12 months after surgery. Clinical Controls: 1 day, 1 and 3 weeks, 6 and 12 months after surgery. | 6 months. CBCT images: preoperative and 6 months after surgery. Clinical controls: every week during the first month; every month for the next 5 months. | 6 months. CBCT images: preoperative and 6 months after surgery. | 9 months. Radiographic assessment: preoperative; immediate, 3, 6 and 9 months postoperative. |
|
| PRF group did not have a significant increase in the thickness, height, and density of alveolar bone graft. | Averagely 69.5% of alveolar defects were regenerated with bone in experimental group and 73.8% on control group ( | Experimental group demonstrated 90% of complete alveolar bone union verses 70% in control group. Autologous BMMNCs in combination with autologous PRF and nanohydroxyapatite promote bone regeneration in alveolar clefts defects. | Postoperative newly formed bone volume was better in the experimental group (68.21%) than in control group (64.62%). Although, no statistically significant difference was found. | The mean amount and percentage of newly formed bone volume was higher in the experimental (0.78 cm3; 82.6%) than control group (0.62 cm3; 68.38%). Bone density does not increase, but the difference was not statistically significant. | PRF in combination with autogenous bone results in higher osteogenic effect which increases new bone regeneration and better wound healing. |
RCT, randomized controlled trial. PRF, platelet-rich fibrin. SD, standard deviation. CBCT, cone beam computer tomography. L-PRF, leucocyte- and platelet-rich fibrin. BMMNCs, bone marrow mononuclear cells. CT, computed tomography scan.
Characteristics of included studies on tooth movement and post-orthodontic stability.
| Tooth Movement and Post-Orthodontic Stability | |||
|---|---|---|---|
|
| Muñoz et al. [ | Tehranchi et al. [ | Nemtoi et al. [ |
|
| 2016 | 2018 | 2018 |
|
| Cohort | Split mouth clinical trial RCT | Split mouth clinical trial CCT |
|
| Effect of L-PRF in PAOO concerning post-operative pain, inflammation, infection and post-orthodontic stability. | Effect of LPRF on OTM in extraction cases. | Efficacy of PRF in accelerating bone regeneration and orthodontic tooth movement. |
|
| Wilcko’s modified PAOO technique combined with L-PRF | Extraction socket with LPRF (n = 15) | Extraction socket with LPRF (n = 20) |
|
| NA | Extraction socket with secondary healing (n = 15) | Extraction socket with secondary healing (n = 20) |
|
| 11 (8/3) | Thirty extraction sockets in 8 patients (3/5) | Forty extraction sockets in 20 patients (11/9) |
|
| 15–51 | 12–25 (17.37 ± 12.48) | 12–20 (16.43) |
|
| 3000 rpm, 10 min | 2700 rpm, 12 min | 2700 rpm, 12 min |
|
| Clinical parameters and patient feedback were used to evaluate pain, post-surgical inflammation and infection. | OTM was measured by comparing the change in horizontal linear distance between the mid-marginal ridges of the adjacent teeth on a regular basis. | CBCT images (PlanmecaPromax 3D Mid, Planmeca OY, Helsinki, Finland). Exposure conditions: 90 kV, 12 mA, and exposure time of 18.3 s. OTM was measured by comparing the change in horizontal linear distance between the mid-marginal ridges of the adjacent teeth on a regular basis. |
|
| Clinical evaluation: 1, 2, 4, 8 and 10 days post-operative. | 16 weeks. OTM measurements: 2, 4, 6, 8, 10, 12, 14 and 16 weeks. | 24 weeks. OTM measurements: before placement of PRF; 4, 8, 12, 16, 20 and 24 weeks after placement of PRF. |
|
| (1) No severe pain; (2) Edema resolution begun by day 4 with most patients (72.7%); (3) Orthodontic treatment average time was 9.3 months; (4) All cases maintained stability for at least 2 years. | LPRF group: decreased horizontal linear measurement between the mid marginal ridges of teeth ( | PRF group: decreased horizontal linear measurement between the mid marginal ridges of teeth. Therefore, LPRF may accelerate OTM, particularly in extraction cases. |
RCT, randomized controlled trial. PRF, platelet-rich fibrin. SD, standard deviation. CBCT, cone beam computer tomography. L-PRF, leucocyte- and platelet-rich fibrin. PAOO, periodontally accelerated osteogenic orthodontics. OTM, orthodontic tooth movement. CCT, controlled clinical trial.
Figure 2Risk of bias of the RCTs and CCTs studies. + low risk of bias. ? unclear risk of bias. – high risk of bias.